Kiadis submits MAA for HSCT adjunct ATIR101

Kiadis Pharma N.V. (Euronext:KDS) submitted an MAA to EMA for ATIR101 as an adjunct therapy to hematopoietic stem cell transplantation (HSCT) for hematological cancers. The company expects a decision in 2H18 and hopes to launch the product in the EU in 2019.

The product is a T lymphocyte-enriched leukocyte preparation depleted ex vivo of host alloreactive T cells using photodynamic treatment...